{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:58:11Z","timestamp":1790420291502,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","award":["2019\u2010004497\u201025"],"award-info":[{"award-number":["2019\u2010004497\u201025"]}],"id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>In the phase 3b, randomized, double\u2010blind, placebo\u2010controlled DELIVER clinical trial, eptinezumab reduced migraine frequency and headache in adults with two to four prior preventive treatment failures. Here, the effect of eptinezumab on coinciding patient\u2010reported outcomes is reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults were randomized to receive eptinezumab 100, 300\u2009mg or placebo intravenously at weeks 12 and 24. The EQ\u20105D\u20105L, measuring overall patient health, and the six\u2010item Headache Impact Test were completed every 4\u2009weeks. The Patient Global Impression of Change was completed at weeks 4, 12 and 24. Patient\u2010identified most bothersome symptom and the Migraine\u2010Specific Quality of Life Questionnaire were administered at weeks 12 and 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eptinezumab improved patient\u2010reported outcomes more than placebo, starting at week 4 and at all subsequent time points. By week 12, patients\u2019 overall health (EQ\u20105D\u20105L visual analog scale score) improved with eptinezumab treatment (difference from placebo in change from baseline: 100\u2009mg, 5.1, 95% confidence interval [CI] 2.2, 8.1,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; 300 mg, 7.5, 95% CI 4.5, 10.4,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). At week 12, eptinezumab improved headache\u2010related quality of life (difference from placebo in change from baseline in Headache Impact Test total score: 100\u2009mg, \u22123.8, 95% CI \u22125.0, \u22122.5,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001; 300 mg, \u22125.4, 95% CI \u22126.7, \u22124.2,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), including each Migraine\u2010Specific Quality of Life Questionnaire domain (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.0001, all comparisons). Over twice as many patients receiving eptinezumab than placebo reported much or very much improvement on the Patient Global Impression of Change and patient\u2010identified most bothersome symptom.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with two to four prior preventive treatment failures receiving eptinezumab versus placebo reported greater improvements in well\u2010being, quality of life and most bothersome symptoms compared to placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">ClinicalTrials<\/jats:styled-content>.gov identifier:<jats:styled-content style=\"fixed-case\">NCT04418765<\/jats:styled-content>;<jats:styled-content style=\"fixed-case\">EudraCT<\/jats:styled-content>identifier: 2019\u2010004497\u201025.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.15670","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T14:09:01Z","timestamp":1672409341000},"page":"1089-1098","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Eptinezumab improved patient\u2010reported outcomes and quality of life in patients with migraine and prior preventive treatment failures"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"first","affiliation":[{"name":"NIHR SLaM Clinical Research Facility, and Headache Group Wolfson CARD King's College London London UK"},{"name":"Department of Neurology University of California Los Angeles, CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-3755","authenticated-orcid":false,"given":"Piero","family":"Barbanti","sequence":"additional","affiliation":[{"name":"Headache and Pain Unit IRCCS San Raffaele Rome Italy"},{"name":"San Raffaele University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[{"name":"The Headache Service Guy's and St Thomas' Hospitals NHS Trust London UK"},{"name":"Institute of Psychiatry, Psychology and Neuroscience King's College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie Laurberg","family":"Christoffersen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Krog","family":"Josiassen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Phul","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/S10194-022-01402-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/HEAD.13966"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416636055"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20100"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00757.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.264671"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.11.007"},{"issue":"15","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P1.10-025","article-title":"Early impact of eptinezumab on the health\u2010related quality of life (HRQoL) of patients with episodic or chronic migraine: SF\u201036 analysis across the spectrum of migraine","volume":"92","author":"Diamond M","year":"2019","journal-title":"Neurology"},{"issue":"15","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P2.10-007","article-title":"Eptinezumab meaningfully improves quality of life (QoL) in patients with episodic or chronic migraine within 1 month after treatment (P2.10\u2010007)","volume":"92","author":"Spierings E","year":"2019","journal-title":"Neurology"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02123-w"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00185-5"},{"key":"e_1_2_11_24_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2);2016. Accessed July 9 2022.https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.05.010"},{"key":"e_1_2_11_30_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14295"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01386-z"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7665"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01376-7"},{"issue":"1","key":"e_1_2_11_38_1","first-page":"116","article-title":"Optimization of acute treatment and headache\u2010related impact following eptinezumab initiated during a migraine attack: post hoc analysis of the RELIEF study","volume":"62","author":"Buse DC","year":"2022","journal-title":"Headache"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02774-3"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13946"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00996-2"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32534-0"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1457533"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03101-6"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.2196\/10178"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0295-6"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.15670","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T06:57:46Z","timestamp":1728629866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.15670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/ene.15670"],"URL":"https:\/\/doi.org\/10.1111\/ene.15670","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"2022-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}